$7.98
1.12% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US30233G1004
Symbol
EYPT
Sector
Industry

EyePoint Pharmaceuticals, Inc. Stock price

$7.98
-1.11 12.21% 1M
-12.83 61.65% 6M
-15.13 65.47% YTD
-0.18 2.21% 1Y
-3.48 30.37% 3Y
-10.02 55.67% 5Y
-35.02 81.44% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.09 1.12%
ISIN
US30233G1004
Symbol
EYPT
Sector
Industry

Key metrics

Market capitalization $431.89m
Enterprise Value $174.93m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.47
P/S ratio (TTM) P/S ratio 8.57
P/B ratio (TTM) P/B ratio 1.84
Revenue growth (TTM) Revenue growth 34.98%
Revenue (TTM) Revenue $50.39m
EBIT (operating result TTM) EBIT $-98.62m
Free Cash Flow (TTM) Free Cash Flow $-94.36m
Cash position $280.25m
EPS (TTM) EPS $-1.80
P/E forward negative
P/S forward 10.45
EV/Sales forward 4.23
Short interest 19.96%
Show more

Is EyePoint Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

EyePoint Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from EyePoint Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
50 50
35% 35%
100%
- Direct Costs 4.36 4.36
46% 46%
9%
46 46
57% 57%
91%
- Selling and Administrative Expenses 48 48
16% 16%
96%
- Research and Development Expense 95 95
70% 70%
189%
-98 -98
16% 16%
-194%
- Depreciation and Amortization 0.89 0.89
30% 30%
2%
EBIT (Operating Income) EBIT -99 -99
15% 15%
-196%
Net Profit -87 -87
18% 18%
-172%

In millions USD.

Don't miss a Thing! We will send you all news about EyePoint Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EyePoint Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
24 days ago
- Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 - - Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 -
Positive
Seeking Alpha
29 days ago
EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boosted EyePoint's stock, but concerns remain about efficacy, financial strength, competition, and patient/physician adoption. A recent NPDR study failure caused a significant stock drop, but upcoming ...
Neutral
GlobeNewsWire
about one month ago
WATERTOWN, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:
More EyePoint Pharmaceuticals, Inc. News

Company Profile

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Duker
Employees 121
Founded 1987
Website www.eyepointpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today